General
Preferred name
ALEPLASININ
Synonyms
PAZ 417 ()
PAZ417 ()
PAZ-417 ()
Aleplasinina ()
Aleplasinine ()
P&D ID
PD058500
CAS
481629-87-2
Tags
available
drug candidate
Drug indication
Alzheimer disease
Drug Status
investigational
Max Phase
2.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Aleplasinin is an orally active, potent, BBB-penetrated and selectiveSERPINE1 (PAI-1, Plasminogen activator inhibitor-1) inhibitor. Aleplasinin increases amyloid-¦Â (A¦Â) catabolism and ameliorates amyloid-related pathology. Aleplasinin improves memory deficiency. Aleplasinin can be used for Alzheimer's disease research[1][2].
PRICE 175
DESCRIPTION Aleplasinin (PAZ 417) is a selective and orally active inhibitor of Plasminogen activator inhibitor-1(PAI-1) and a key negative regulator of the fibrinolytic system. Aleplasinin can be used in Alzheimer's disease studies. (TargetMol Bioactive Compound Library)
Compound Sets
8
Cayman Chemical Bioactives
42122
ChEMBL Drugs
CHEMBL325424
DrugBank
DB12635
DrugMAP
DMYTIP4
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL325424
MedChem Express Bioactive Compound Library
HY-14759
ReFrame library
TargetMol Bioactive Compound Library
T29856
External IDs
18
Properties
(calculated by RDKit )
Molecular Weight
425.2
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
1
Rotatable Bonds
5
Ring Count
4
Aromatic Ring Count
4
cLogP
6.23
TPSA
59.3
Fraction CSP3
0.21
Chiral centers
0.0
Largest ring
6.0
QED
0.3
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
PAI-1
Amyloid-β
Amyloid-¦Â
Pathway
Metabolic Enzyme/Protease
Neuronal Signaling
Metabolism
Source data